S2E6: PCOS Is Now PMOS: What the Name Change Means for Every Era of Your Hormonal Life
Welcome to Clearly Hormonal
(formerly Reset Recharge)
S2 E6
On May 12, 2026, The Lancet published the results of a 14-year global effort: Polycystic Ovarian Syndrome (PCOS) has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). For over 170 million women worldwide — most of whom have never received a correct diagnosis — this is not just a nomenclature update. It is a reckoning.
In this episode, Dr. Komal Patil-Sisodia breaks down what changed, what didn’t, and why the new name carries profound clinical implications across every hormonal era: adolescence, the reproductive years, perimenopause, and menopause and beyond. She connects the renaming to the 2026 ACC/AHA dyslipidemia guidelines, the 70% undiagnosis rate, and the lifelong metabolic consequences that the old name made invisible.
If you’ve ever been handed a birth control pill without a workup, told your symptoms were stress, or felt dismissed in a clinical setting — this episode is for you.
PCOS Is Now PMOS: What the Name Change Means for Every Era of Your Hormonal Life
By Dr. Komal Patil-Sisodia, MD | Eastside Menopause & Metabolism
On May 12, 2026, something landed in The Lancet that genuinely stopped me in my tracks. PCOS has a new name.
Polycystic Ovarian Syndrome is now officially Polyendocrine Metabolic Ovarian Syndrome — PMOS. One letter changed: C to M. And if your first reaction is “a name change, that’s the big news?” — I want you to stay with me. Because in medicine, what we call something determines everything that happens next. Who gets diagnosed. How they get treated. How seriously they’re taken. What their future looks like.
For the over 170 million women worldwide living with this condition — most of whom have never received a correct diagnosis — that old name has been doing real damage for a long time.
Why the Old Name Was Wrong
The renaming wasn’t a marketing decision. It was the result of a 14-year global scientific effort led by Professor Helena Teede at Monash University in Australia, involving 56 leading academic, clinical, and patient organizations — including The Endocrine Society — and over 22,000 survey responses from patients and clinicians across every world region. The Lancet paper was unambiguous: the old name was scientifically inaccurate, and that inaccuracy caused real harm.
The word “polycystic” told doctors and patients that this was a condition about ovarian cysts. And because cysts were the headline, everything else got minimized: the insulin resistance, the androgen dysregulation, the cardiovascular risk, the metabolic consequences that build quietly over decades. A related paper from the same research group confirmed what many of us have known clinically for years — there is no significant increase in pathologic ovarian cysts in this condition. The follicles visible on ultrasound reflect disrupted ovulation. They are not the disease itself.
What PMOS Actually Means
Let’s take the new name word by word.
Polyendocrine. This means multiple interacting hormonal disturbances — not one rogue hormone, but a system-level disruption involving insulin, androgens, and neuroendocrine signaling all working against each other.
Metabolic. This is the word that changes everything clinically. Insulin resistance, elevated risk for type 2 diabetes, dyslipidemia, cardiovascular risk — these are not side effects or coincidences. They are core features. And the 2026 American College of Cardiology and American Heart Association dyslipidemia guidelines now formally recognize conditions like PMOS as cardiovascular risk enhancers.
Ovarian dysfunction — the disrupted follicle development and disturbance in ovulation — still remains a defining feature. But the ovary is just one part of the story. It’s not the whole story anymore.
And polycystic is gone. That word has been misdirecting care for generations.
What Didn’t Change
The diagnostic criteria did not change. The Rotterdam criteria — requiring two of three features: irregular ovulation, clinical or biochemical androgen excess, and polycystic ovarian morphology on ultrasound — remain intact. If you were diagnosed with PCOS under existing criteria, that diagnosis is valid. You have PMOS. Nothing about your clinical picture needs to be readdressed. What changed is the language used to describe what you have — language that finally reflects the full biological reality of this condition.
Four Eras, One Condition
Here’s what I find most important about this renaming: PMOS doesn’t live only in one chapter of a woman’s life. It shows up in every era. And what gets missed in each era — because of the wrong name, the wrong framing, the wrong questions being asked — compounds over a lifetime.
Adolescence: The Era of Missed Beginnings
Think about what puberty looks like for a young woman who has PMOS but doesn’t know it yet. Her periods are irregular, but she’s told that’s normal in the first few years. Her skin breaks out — just teenage acne. She’s gaining weight around her midsection without any change in her diet. Hair is growing in places that feel wrong and thinning in places that feel frightening. And almost universally, she hears: “Give it time. Here’s the birth control pill.”
Hormonal contraception can be an appropriate tool for PMOS management. But when it’s handed to a teenager without metabolic investigation, without any workup for insulin resistance or androgen excess, it becomes a lid on a pot that’s still boiling. The symptoms quiet. The underlying condition progresses. And the diagnosis gets delayed by years — sometimes a decade.
We know that early treatment of insulin resistance can restore spontaneous ovulation, reduce androgen excess, and meaningfully change the metabolic trajectory of this condition. The window in adolescence is not one you wait through. It’s one you can act in. And the word metabolic in the new name changes what gets asked in that adolescent visit.
Reproductive Years: The Era of Diagnosis and Distraction
For most women, the reproductive years are when PMOS finally gets a name — but often only because of trouble getting pregnant. By the time a woman is sitting in a fertility clinic receiving this diagnosis, she may have had over a decade of symptoms that were dismissed. And the conversation centers almost entirely on ovulation induction and IVF. Those are critically important conversations. But they’re not the whole conversation.
What about the insulin resistance that has been driving this for years? What about the cholesterol patterns? What about the fact that pregnancy in a woman with unoptimized PMOS carries higher risks for gestational diabetes, preeclampsia, and preterm birth — risks that can be meaningfully reduced with preconceptual metabolic care?
The fertility conversation and the metabolic conversation are not separate. They should never be treated as if they are. PMOS is not a fertility problem with extra symptoms. It is a metabolic condition with reproductive implications. That reframe matters in the exam room.
Perimenopause: The Era That Intensifies
For a woman with PMOS, perimenopause is where the metabolic picture often intensifies — and almost no one is prepared for it, because no one connects the dots across her hormonal life. As ovarian function begins to decline, the hormonal scaffolding that was providing some structure shifts. For women with underlying insulin resistance, this transition often brings worsening metabolic features: accelerated visceral fat accumulation, higher blood sugars, increasingly abnormal cholesterol, rising blood pressure.
Some women with PMOS actually experience more regular cycles in their 30s and early 40s. Their symptoms quiet. They may feel they’ve “outgrown” the diagnosis. They haven’t. The metabolic dysfunction is still present, and perimenopause will often surface it again — more loudly, and in new ways.
Menopause and Beyond: The Era the Name Change Protects
When we arrive at menopause, the ovarian story is largely over. And under the old framing, you might assume the condition closed with it. It doesn’t. The metabolic story does not end at menopause. In fact, for women with PMOS, the post-menopausal years may represent the period of highest cardiovascular risk — risk that has been building for decades without adequate clinical attention, because no one was framing this as a lifelong metabolic condition.
The 2026 ACC/AHA dyslipidemia guideline now formally recognizes reproductive and hormonal conditions as cardiovascular risk enhancers, meaning a woman’s history of PMOS should be actively informing her lifetime cardiovascular risk assessment. It should not be a footnote in an old OB chart. If you are post-menopausal and have a history of PCOS, ask about your cardiovascular risk assessment. Ask whether Lp(a) and ApoB have been checked — both are now Class 1 universal screening in the 2026 guidelines.
One Name. Four Eras. A Different Clinical Posture.
In adolescence, polyendocrine tells a clinician: look at the whole hormonal system. Don’t just hand her a pill. In the reproductive years, metabolic tells a clinician: this woman’s fertility struggles exist inside a metabolic context. In perimenopause, polyendocrine metabolic says: this transition is going to be complex; she needs a long-term plan. In menopause and beyond, metabolic says: this story is not over. The ovarian chapter closed, but the metabolic chapter is still being written.
For the women who have lived this — who spent years being dismissed, handed birth control without a workup, told to lose weight without the metabolic tools to do it, told their symptoms were anxiety or just part of being a woman — I want you to hear this clearly:
“You were not wrong about your body. The name was wrong about your condition.”— Dr. Komal Patil-Sisodia
Your symptoms across your entire hormonal life are connected. They are not separate, unrelated problems. They are expressions of one underlying endocrine and metabolic condition, and you deserve care that addresses all of it at every stage.
That’s what I’m here to do. That’s what this show is for.
Listen to this episode of Clearly Hormonal wherever you get your podcasts, or find it at eastsidemm.com/podcast.
Follow Dr. Komal Patil-Sisodia:@drpatilsisodia on Instagram and TikTok
This content is for educational purposes only and does not constitute personalized medical advice. Please discuss your specific health concerns with your own healthcare provider.
Dr. Komal Patil-Sisodia is a triple board-certified physician (Internal Medicine, Endocrinology, Obesity Medicine) and Menopause Society Certified Practitioner. She is the founder of Eastside Menopause & Metabolism and host of the Clearly Hormonal podcast.